Form 4: Moderna Director Noubar Afeyan Sells Shares Under 10b5-1 Trading Plan

Noubar Afeyan, a director at Moderna, sold shares of the company's common stock on April 10, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On April 10, 2024, Noubar Afeyan, a director of Moderna, sold shares of the company's common stock.
• The sales were executed under a Rule 10b5-1 trading plan adopted on February 27, 2023, and amended on November 7, 2023.
• Afeyan sold 6,351 shares at a weighted average price of $106.5945, 7,512 shares at $107.3131, 748 shares at $108.5631, and 389 shares at $109.3628.
• Following these transactions, Afeyan directly owns 2,071,931 shares of Moderna common stock.
• Afeyan also has indirect ownership through Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P. (9,662,114 shares) and Flagship Pioneering, Inc. (3,924 shares).
• Afeyan disclaims beneficial ownership of shares held by Flagship Ventures Fund IV, L.P., Flagship Ventures Fund IV-Rx, L.P., and Flagship Pioneering, Inc. except to the extent of his pecuniary interest therein.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating stock sales by a company director. It doesn't inherently convey positive or negative sentiment, as it's a routine disclosure. The sales were conducted under a pre-arranged 10b5-1 trading plan.

Industry Context

Sales by insiders are a common occurrence and are often pre-planned, especially when executed under Rule 10b5-1 trading plans. These plans allow insiders to sell shares over a period of time without being accused of trading on non-public information.

Stakeholder Impact

• The stock sale could have a minor impact on shareholder sentiment, but given the pre-planned nature of the transaction, it's unlikely to cause significant concern.
• The impact on other stakeholders (employees, customers, suppliers, creditors) is expected to be minimal.

Key Dates